SCHEMBL10167016

SCHEMBL10167016

CN(c1ccc(S(=O)(=O)c2ccccc2)cc1Cl)S(=O)(=O)CCl

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NR1H3 Q13133 1/20 0.43
ALDH1A1 P00352 5/20 0.40
POLB P06746 3/20 0.40
MAPT P10636 3/20 0.40
SMN1; SMN2 Q16637 3/20 0.40
CYP3A4 P08684 1/20 0.40
CYP2C9 P11712 1/20 0.40
CYP2C19 P33261 1/20 0.40
HTR6 P50406 4/20 0.39
LMNA P02545 3/20 0.38
L3MBTL1 Q9Y468 1/20 0.38
SFRP1 Q8N474 1/20 0.37
CRHBP P24387 1/20 0.37
CRHR2 Q13324 1/20 0.37
HPGD P15428 2/20 0.36
SLC16A1 P53985 1/20 0.36
KDM4E B2RXH2 1/20 0.36
ALOX15 P16050 1/20 0.36
HSD17B10 Q99714 1/20 0.36
MEN1 O00255 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2458633 0.71 HTR6 (0.58) ALDH1A1POLBMAPTSMN1; SMN2CYP3A4
SCHEMBL10167015 0.71 RORC (0.38) ALDH1A1POLBMAPTSMN1; SMN2CYP3A4
SCHEMBL1755239 0.71 ALDH1A1 (0.64) ALDH1A1POLBMAPTSMN1; SMN2HTR6
SCHEMBL16481025 0.68 ALDH1A1 (0.51) ALDH1A1POLBMAPTSMN1; SMN2HTR6
SCHEMBL4199324 0.67 HTR6 (0.52) ALDH1A1POLBMAPTSMN1; SMN2CYP3A4
SCHEMBL9805864 0.67 HTR6 (0.52) ALDH1A1POLBMAPTSMN1; SMN2CYP3A4
SCHEMBL2908734 0.67 HTR6 (0.52) ALDH1A1POLBMAPTSMN1; SMN2CYP3A4
SCHEMBL11112123 0.67 CA12 (0.61) ALDH1A1POLBMAPTSMN1; SMN2CYP3A4
SCHEMBL30973847 0.67 HTR6 (0.52) ALDH1A1POLBMAPTSMN1; SMN2CYP3A4
SCHEMBL10975673 0.67 TSHR (0.58) ALDH1A1POLBMAPTHTR6LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8692001-B2 Sulfonamides for the modulation of PKM2 DYNAMIX PHARMACEUTICALS LTD. (IL) 2014-04-08 US disclosed
US-8692001-B2 Sulfonamides for the modulation of PKM2 DYNAMIX PHARMACEUTICALS LTD. (IL) 2014-04-08 US disclosed
WO-2012056319-A1 SULFONAMIDES FOR THE MODULATION OF PKM2 DYNAMIX PHARMACEUTICALS LTD. (IL) 2012-05-03 WO disclosed
US-20120108631-A1 Sulfonamides for the Modulation of PKM2 DYNAMIX PHARMACEUTICALS LTD. (IL) 2012-05-03 US disclosed
US-20120108631-A1 Sulfonamides for the Modulation of PKM2 DYNAMIX PHARMACEUTICALS LTD. (IL) 2012-05-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120108631-A1 Sulfonamides for the Modulation of PKM2 PDK1, PDK4, PDK2 NR1H3 2862/4885ALDH1A1 2275/4885POLB 4129/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.